[Overseas Network May 4 | Full Epidemic Time Zone] Former Director of the US Food and Drug Administration (FDA) Scott Gottlieb warned on Sunday that if states allow schools, businesses and other public If the venue relaxes vigilance, then the new coronary disease in the United States may usher in a "new epidemic" or "large-scale outbreak."
According to the US political news website "politico", Gottlieb said in an interview with CBS's "Face the Nation" program on the 3rd: "The worry is that the epidemic will probably Continue to spread continuously. "
"Although domestic prevention and control measures cannot be said to have failed, I think it has not achieved the expected results." Gottlieb admitted frankly, "We had expected that at this time, the number of newly confirmed cases and deaths across the country should have begun A substantial drop, and we are not seeing this now. "
Gottlieb pointed out that the epidemic is still spreading in about 20 states in the United States. At the same time, different parts of the United States are slowly reopening in different ways. Gottlieb said, "There are 20,000 to 30,000 new confirmed cases and thousands of new deaths every day. This situation should last for the entire summer." Gottlieb added that when people start to relax their vigilance, Restart work, so that the "relatively mild" situation may also change into a new epidemic or large-scale outbreak at any time.
Looking forward to the fall, Gottlieb agreed that the new drug ridxivir should be a way to control the infection rate of the new crown, while also relying on other antibody drugs and available vaccines. He emphasized: "The government has accepted the fact that the epidemic continues to spread, and is eager to open the economy in this context. Then it should be more reinvested in related research and development work, and ensure that it does everything possible to prepare these things before the arrival of autumn . "
Gottlieb is 47 years old and a Republican. During the administration of former US President George W. Bush, he was deputy director of the FDA. Trump nominated him as the Director of the FDA in March 2017. Gottlieb's "work performance" at the FDA has been "praised" by many Republicans and Democrats because he advocates curbing young people from smoking e-cigarettes, speeding up approval of generic drugs to reduce drug prices, and stimulating new drugs and new technologies R & D encourages competition. In March last year, Gottlieb announced his departure, expressing the hope that he would spend more time with his family. (Overseas Network Zhao Kuan)